Literature DB >> 11419910

Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells.

X Zhao1, Y Q Wei, Z L Peng.   

Abstract

The loading of dendritic cells (DCs) with whole tumor cell lysates may circumvent the facts that few tumor-specific antigens have been identified in human solid tumors. The present study was designed to investigate whether ovarian cancer cells lysate-pulsed DCs activate T cell responses against autologous ovarian tumors. Incubation of T cells with autologous tumor cell lysate-pulsed DCs stimulated proliferation of autologous T cells. T cells primed by autologous tumor cell lysate-pulsed DCs showed significant killing activity against autologous tumor cells, which could be blocked by anti-MHC-class-I and anti-CD8 mAb. By contrast, T cells primed by autologous unpulsed DCs alone or tumor lysates alone failed to exhibit significant killing activity. In addition, T cells primed by DCs pulsed with allogeneic tumor cell lysates or with autologous normal cell lysate or by these cell lysates alone did not induce the increase in the autologous tumor killing activity. As additional controls, T cells stimulated with autologous tumor lysate-pulsed DCs express no increase in the lysis of autologous monocytes, allogeneic ovarian tumor cells and other cell lines including K562, Daudi and Molt-4. Furthermore, T cells stimulated with autologous tumor lysate-pulsed DCs could produce the considerable amounts of cytokines such as GM-CSF, TNF-alpha and IFN-gamma. The data in the present study suggest that whole tumor cell lysates-pulsed DCs could activate T cell responses against autologous ovarian tumor cells, and that these pulsed DCs may be used as a new approach for the specific immunotherapy of ovarian cancer patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11419910     DOI: 10.1081/imm-100103689

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  8 in total

1.  Th1 Immune Response Induction by Biogenic Selenium Nanoparticles in Mice with Breast Cancer: Preliminary Vaccine Model.

Authors:  Mohammad Hossein Yazdi; Mehdi Mahdavi; Elnaz Faghfuri; Mohammad Ali Faramarzi; Zargham Sepehrizadeh; Zuhair Mohammad Hassan; Mehdi Gholami; Ahmad Reza Shahverdi
Journal:  Iran J Biotechnol       Date:  2015-06       Impact factor: 1.671

Review 2.  Past, present and future targets for immunotherapy in ovarian cancer.

Authors:  Carlton L Schwab; Diana P English; Dana M Roque; Monica Pasternak; Alessandro D Santin
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

3.  Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.

Authors:  Douglas J Hanlon; Paulomi B Aldo; Lesley Devine; Ayesha B Alvero; Anna K Engberg; Richard Edelson; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2011-01-18       Impact factor: 3.886

Review 4.  Cellular immunotherapy for ovarian cancer.

Authors:  Martin J Cannon; Timothy J O'Brien
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

5.  Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.

Authors:  Bridget Charbonneau; Kirsten B Moysich; Kimberly R Kalli; Ann L Oberg; Robert A Vierkant; Zachary C Fogarty; Matthew S Block; Matthew J Maurer; Krista M Goergen; Brooke L Fridley; Julie M Cunningham; David N Rider; Claudia Preston; Lynn C Hartmann; Kate Lawrenson; Chen Wang; Jonathan Tyrer; Honglin Song; Anna deFazio; Sharon E Johnatty; Jennifer A Doherty; Catherine M Phelan; Thomas A Sellers; Starr M Ramirez; Allison F Vitonis; Kathryn L Terry; David Van Den Berg; Malcolm C Pike; Anna H Wu; Andrew Berchuck; Aleksandra Gentry-Maharaj; Susan J Ramus; Brenda Diergaarde; Howard Shen; Allan Jensen; Janusz Menkiszak; Cezary Cybulski; Jan Lubiłski; Argyrios Ziogas; Joseph H Rothstein; Valerie McGuire; Weiva Sieh; Jenny Lester; Christine Walsh; Ignace Vergote; Sandrina Lambrechts; Evelyn Despierre; Montserrat Garcia-Closas; Hannah Yang; Louise A Brinton; Beata Spiewankiewicz; Iwona K Rzepecka; Agnieszka Dansonka-Mieszkowska; Petra Seibold; Anja Rudolph; Lisa E Paddock; Irene Orlow; Lene Lundvall; Sara H Olson; Claus K Hogdall; Ira Schwaab; Andreas du Bois; Philipp Harter; James M Flanagan; Robert Brown; James Paul; Arif B Ekici; Matthias W Beckmann; Alexander Hein; Diana Eccles; Galina Lurie; Laura E Hays; Yukie T Bean; Tanja Pejovic; Marc T Goodman; Ian Campbell; Peter A Fasching; Gottfried Konecny; Stanley B Kaye; Florian Heitz; Estrid Hogdall; Elisa V Bandera; Jenny Chang-Claude; Jolanta Kupryjanczyk; Nicolas Wentzensen; Diether Lambrechts; Beth Y Karlan; Alice S Whittemore; Hoda Anton Culver; Jacek Gronwald; Douglas A Levine; Susanne K Kjaer; Usha Menon; Joellen M Schildkraut; Celeste Leigh Pearce; Daniel W Cramer; Mary Anne Rossing; Georgia Chenevix-Trench; Paul D P Pharoah; Simon A Gayther; Roberta B Ness; Kunle Odunsi; Lara E Sucheston; Keith L Knutson; Ellen L Goode
Journal:  Cancer Immunol Res       Date:  2014-01-27       Impact factor: 11.151

Review 6.  Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.

Authors:  Yu-Zhe Chen; Xing-Lei Yao; Yasuhiko Tabata; Shinsaku Nakagawa; Jian-Qing Gao
Journal:  Clin Dev Immunol       Date:  2010-12-20

Review 7.  Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer.

Authors:  Vincent Lavoué; Aurélie Thédrez; Jean Levêque; Fabrice Foucher; Sébastien Henno; Vincent Jauffret; Marc-Antoine Belaud-Rotureau; Veronique Catros; Florian Cabillic
Journal:  J Transl Med       Date:  2013-06-13       Impact factor: 5.531

8.  Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells.

Authors:  Jiyun Yu; Rong Tian; Bingshui Xiu; Jinqi Yan; Rui Jia; Liang Zhang; Alfred E Chang; Hongbin Song; Qiao Li
Journal:  Int J Biol Sci       Date:  2009-01-20       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.